162 related articles for article (PubMed ID: 22210270)
41. Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.
Xu F; Dong Y; Huang X; Chen P; Guo F; Chen A; Huang S
Mol Med Rep; 2016 Sep; 14(3):2289-96. PubMed ID: 27430581
[TBL] [Abstract][Full Text] [Related]
42. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin.
Shiotani A; Takami M; Itoh K; Shibasaki Y; Sasaki T
Anat Rec; 2002 Oct; 268(2):137-46. PubMed ID: 12221720
[TBL] [Abstract][Full Text] [Related]
43. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture.
Komine M; Kukita A; Kukita T; Ogata Y; Hotokebuchi T; Kohashi O
Bone; 2001 May; 28(5):474-83. PubMed ID: 11344046
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of osteoclastogenesis by RNA interference targeting RANK.
Ma R; Xu J; Dong B; Kauther MD; Jäger M; Wedemeyer C
BMC Musculoskelet Disord; 2012 Aug; 13():154. PubMed ID: 22913338
[TBL] [Abstract][Full Text] [Related]
45. Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones.
Woo KM; Choi Y; Ko SH; Ko JS; Oh KO; Kim KK
Exp Mol Med; 2002 Nov; 34(5):347-52. PubMed ID: 12526098
[TBL] [Abstract][Full Text] [Related]
46. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
Nagata N; Kitaura H; Yoshida N; Nakayama K
Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
[TBL] [Abstract][Full Text] [Related]
48. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities.
Wittrant Y; Theoleyre S; Couillaud S; Dunstan C; Heymann D; Rédini F
Exp Cell Res; 2004 Feb; 293(2):292-301. PubMed ID: 14729467
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
[TBL] [Abstract][Full Text] [Related]
50. Osteoprotegerin-Knockout Mice Developed Early Onset Root Resorption.
Liu Y; Du H; Wang Y; Liu M; Deng S; Fan L; Zhang L; Sun Y; Zhang Q
J Endod; 2016 Oct; 42(10):1516-22. PubMed ID: 27663616
[TBL] [Abstract][Full Text] [Related]
51. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
52. [RANKL and OPG expression in bone marrow-derived mesenchymal stem cells of ovariectomied promotes osteoclast development and enhances its function].
Shao B; Yu Y; Fu X; Xue H; Qi M; Shuai Y; Zhou Z; Jin Y; Yang D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Dec; 29(12):1262-6. PubMed ID: 24321069
[TBL] [Abstract][Full Text] [Related]
53. (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.
Shen Y; Jiang T; Wang R; He S; Guo M; Zuo J; He D
BMC Complement Altern Med; 2015 Mar; 15():77. PubMed ID: 25887296
[TBL] [Abstract][Full Text] [Related]
54. [Genomic approaches to bone and joint diseases. Mutations of RANK, OPG and RANKL genes found in humans].
Kobayashi Y; Takahashi N
Clin Calcium; 2008 Feb; 18(2):202-9. PubMed ID: 18245890
[TBL] [Abstract][Full Text] [Related]
55. IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells.
Kitami S; Tanaka H; Kawato T; Tanabe N; Katono-Tani T; Zhang F; Suzuki N; Yonehara Y; Maeno M
Biochimie; 2010 Apr; 92(4):398-404. PubMed ID: 20045440
[TBL] [Abstract][Full Text] [Related]
56. Regulation of osteoclastogenesis by gap junction communication.
Matemba SF; Lie A; Ransjö M
J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
[TBL] [Abstract][Full Text] [Related]
57. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
58. Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL).
Suzuki T; Suda N; Ohyama K
J Bone Miner Metab; 2004; 22(3):185-91. PubMed ID: 15108059
[TBL] [Abstract][Full Text] [Related]
59. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
Huang L; Xu J; Wood DJ; Zheng MH
Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
[TBL] [Abstract][Full Text] [Related]
60. Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice.
Oshiro T; Shiotani A; Shibasaki Y; Sasaki T
Anat Rec; 2002 Apr; 266(4):218-25. PubMed ID: 11920384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
